ArticleExperimental dermatology2026
A Specific Signature of Circulating Free Fatty Acid Discriminates Bullous Pemphigoid From Pemphigus Vulgaris and Healthy Controls.
Article in Experimental dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullous pemphigoid (BP) is an autoimmune skin disorder marked by antibodies targeting basement membrane proteins BP180 and BP230. Recent evidence suggests a role for the gut-skin axis and microbial metabolites, especially short-chain fatty acids (SCFAs), in modulating skin homeostasis and immune responses. In this study, we investigated the gut permeability and evaluated the circulating free fatty acids (FFAs) in BP patients, along with the assessment of the ability of each FFA to discriminate BP patients from both pemphigus vulgaris (PV) patients and healthy controls (HC). Thirty-six BP patients and 36 sex- and age-matched HC were enrolled. In addition, we used a previously examined cohort of 18 PV patients. FFAs were quantified through gas chromatography-mass spectrometry. Serum zonulin levels were measured by ELISA test and then correlated with FFA levels and clinical markers of disease activity. Receiver operating characteristic (ROC) curve analyses evaluated the diagnostic utility of individual FFAs. BP patients had significantly lower SCFA levels but higher medium-chain (MCFAs) and long-chain fatty acids (LCFAs) than HC. Zonulin levels were elevated in BP and correlated negatively with isovaleric acid. No clear associations emerged between FFAs, zonulin and clinical disease severity. Sparse partial least square discriminant analysis identified propionic, octanoic and octadecanoic acids as key discriminators between BP and both HC and PV serum FFAs. These metabolites achieved ROC AUCs > 0.9, showing a strong diagnostic value. Our findings reveal a pro-inflammatory shift in serum FFA profiles in BP-marked by decreased SCFAs and increased MCFAs/LCFAs-concurrent with elevated gut permeability. The strong diagnostic performance of propionic, octanoic and octadecanoic acids highlights their promise as biomarkers for BP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.